Leukaemia
13
4
4
3
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
15.4%
2 terminated out of 13 trials
60.0%
-26.5% vs benchmark
15%
2 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (13)
Digitalized Exercise Fit Tool Intervention for Adolescents With Blood Cancer
xDRIVE for Florida-based Cancer Patients
Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)
Randomised Controlled Trial of Artificial Intelligence-assisted Health Education
PUMA (Paediatric Osseous Marrow Assessment)
Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY)
First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome
High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)
Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML